[Nirmatrelvir/ritonavir (COVID-19, without supplemental oxygen, increased risk of progressing to severe COVID-19, >= 6 years to < 18 years, >= 20 kg)]

Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen
Record ID 32018015781
German
Original Title: Nirmatrelvir/Ritonavir (COVID-19, ≥ 6 Jahre bis < 18 Jahre, ≥ 20 kg)
Details
Project Status: Completed
URL for project: https://www.iqwig.de/projekte/a25-158.html
Year Published: 2026
URL for published report: https://www.iqwig.de/download/a25-158_nirmatrelvir-ritonavir_nutzenbewertung-35a-sgb-v_v1-0.pdf
English language abstract: There is no English language summary available
Publication Type: Full HTA
Country: Germany
DOI: https://doi.org/10.60584/a25-158
MeSH Terms
  • COVID-19
  • COVID-19 Drug Treatment
  • Child
  • Adolescent
  • Antiviral Agents
  • Coronavirus
  • SARS-CoV-2
  • Ritonavir
  • Drug Combinations
Keywords
  • Nirmatrelvir
  • Ritonavir
  • COVID-19
  • Child
  • Adolescent
  • Benefit Assessment
Contact
Organisation Name: Institute for Quality and Efficiency in Health Care (IQWiG)
Contact Address: IQWiG, Siegburger Str. 237, 50679 Cologne, GERMANY, Tel: +49(0)221-35685, Fax: +49(0)221-356851
Contact Email: berichte@iqwig.de
Copyright: Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.